Latest news on BioNTech’s Friday buyout; Unpacking Sarepta’s Duchenne data; Pfizer’s post-Covid plans; Eli Lilly, AstraZeneca’s gene editing deals; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

With earn­ings sea­sons in full swing, the End­points team worked hard to stay on top of Big Phar­ma’s lat­est up­dates as well as break­ing news. Don’t miss our analy­sis on what a stand­ing ova­tion-wor­thy da­ta read­out at ES­MO means for fu­ture clin­i­cal tri­als, the FDA’s shift to­ward ask­ing for more over­all sur­vival da­ta and a Q&A about biotech in­ter­ests on Capi­tol Hill.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.